Physician profile
Taylor Mendell
NPI 1679246862
$3,220.93
in general payments reported to CMS, 2019-2025
22 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8.35 · 2022: $26.60 · 2023: $161 · 2024: $1,491 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.70 | 2023-2025 | |
| Novo Nordisk INC | $449.45 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $435.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $392.56 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $328.37 | 2024-2025 | |
| Glaxosmithkline, LLC. | $210.11 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $118.35 | 2023-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $90.28 | 2024-2025 | |
| Exact Sciences Corporation | $89.10 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.38 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.12 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.50 | 2023-2024 | Xifaxan |
| Lundbeck LLC | $53.36 | 2025 | Rexulti |
| Amgen INC. | $47.36 | 2024-2025 | Otezla, Repatha, Repatha |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.09 | 2024-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $33.68 | 2025 | Sprint Pns System |
| Mannkind Corporation | $30.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.93 | 2024 | |
| Genentech USA, INC. | $21.71 | 2021-2022 | |
| Axsome Therapeutics, INC. | $20.32 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $16.08 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Scynexis, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Mendell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.